Modulation of Cerebral Blood Flow Using Iron Chelators (DFO)

Mass General Brigham

Status and phase: Completed; Early Phase 1

Conditions: Problem of Aging; Stroke

Treatments: Drug: desferrioxamine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT01365104

1K23AG030967-01

1K23AG030967-01A1 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Enrollment: 97 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy adults between the ages of 18-80 years.

Exclusion criteria

• subjects taking vasoactive medications,
• hypertension,
• pregnant women, smokers,
• COPD,
• asthma,
• diabetes mellitus,
• intracranial or carotid stenosis,
• hepatic disease,
• renal disease,
• bone marrow suppression,
• cardiac disease,
• heart failure,
• iron deficiency,
• history of cancer,
• history of head trauma,
• subarachnoid hemorrhage,
• central nervous system vasculitis,
• multiple sclerosis,
• migraines,
• seizures,
• sickle cell disease or trait,
• cardiac arrhythmia,
• unable to give informed consent, or
• poor transcranial Doppler insonation windows.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

97 participants in 2 patient groups

Healthy young

Experimental group

Description:

Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.

Treatment:

Drug: desferrioxamine

healthy old

Experimental group

Description:

Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.

Treatment:

Drug: desferrioxamine